On January 5, 2021 Oncternal Therapeutics (Nasdaq: ONCT), reported that James Breitmeyer, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat hosted by H.C. Wainwright on Monday, January 11, 2021 (Press release, Oncternal Therapeutics, JAN 5, 2021, View Source [SID1234573499]). The discussion may cover Oncternal’s recent progress, upcoming catalysts, and plans for 2021. Please see additional details below:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright BioConnect 2021 Conference (Virtual)

Title: Oncternal Therapeutics (ONCT) Fireside Chat
Date: Monday, January 11th 2021
Time: On-demand starting at 6am EST
Presenter: James Breitmeyer, President & CEO

Webcasting Link:

Click Here
Replay Link:
A replay will be accessible on the Events & Presentations page of the Investors section on the Company’s website at View Source

On January 5, 2021 EDAP TMS SA (Nasdaq: EDAP) ("the Company"), the global leader in robotic energy based therapies, reported that it will participate in the 10th Annual LifeSci Partners Corporate Access Event, January 6-8 and 11-14, 2021 (Press release, EDAP TMS, JAN 5, 2021, View Source [SID1234573498]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Marc Oczachowski, President and CEO, will host 1×1 meetings and will present a corporate update on Thursday, January 7th at 9am EST/ 2pm GMT /3pm CET.

To register to listen to the presentation or to request a meeting, visit: View Source To access the subsequent archived recording of this presentation, please visit the Investor Relations section of the EDAP website or click here.

On January 5, 2021 Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, reported its President and CEO Saiid Zarrabian will present at the H.C. Wainwright Bioconnect 2021 Virtual Conference taking place January 11-14, 2021 (Press release, Kintara Therapeutics, JAN 5, 2021, View Source [SID1234573497]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be available for on-demand listening beginning at 6:00 A.M. Eastern Time on Monday, January 11, 2021, through the close of business January 14, 2021. For those interested in viewing Mr. Zarrabian’s presentation, registration can be accessed here.

On January 5, 2021 Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, reported that the Company will present at the virtual H.C. Wainwright BioConnect 2021 Conference (Press release, Verastem, JAN 5, 2021, View Source [SID1234573496]). The fireside chat will be made available for on-demand listening beginning Monday, January 11, 2021 at 6:00 a.m. EST.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast of the fireside chat will be available on the "Media" section of the Company’s website at www.verastem.com under "Events & Presentations".

On January 5, 2021 iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, reported that Michel Detheux, PhD, President and Chief Executive Officer, will present a company overview at the 39th Annual J.P. Morgan Conference, being held virtually on Tuesday, January 12, 2021 at 9:10 a.m. ET (Press release, iTeos Therapeutics, JAN 5, 2021, View Source [SID1234573494]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the Investors section of the company’s website at View Source An archived replay will be available for approximately 30 days following the presentation.